Claude Science pushes AI-designed protein binders

This is a meaningful step from AI-generated hypotheses toward experimentally validated scientific work, though binder design remains far short of complete drug discovery.

• –Claude handled target selection, computational design, tool use, and iteration with limited human intervention
• –Adaptyv Bio and Twist Bioscience independently built and tested the proposed proteins
• –The results suggest agentic AI can compress specialized protein-design workflows from months toward days
• –Strong binders are only an early proxy; toxicity, delivery, pharmacokinetics, and clinical efficacy remain unresolved
• –Claude Science’s broader significance is its tool-connected workflow, not just the headline hit rate